Skip to main content
Clinical Trials/NCT02821065
NCT02821065
Completed
Not Applicable

TEC4Home: Telehealth for Emergency-Community Continuity of Care Connectivity Via Home-Telemonitoring

University of British Columbia0 sites70 target enrollmentOctober 31, 2016
ConditionsHeart Failure

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure
Sponsor
University of British Columbia
Enrollment
70
Primary Endpoint
Change in number of emergency department revisits 90 day pre and 90 days post enrollment.
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Modern technology like computers, smartphones and the Internet enable patients to measure certain health indicators, like blood pressure and body weight, from the comfort of their own homes. This information can also be shared electronically with doctors and other healthcare providers to monitor remotely. This is called home health monitoring. In TEC4Home, we are developing a home monitoring solution for patients with heart failure to support their care and recovery at home after a visit to the emergency department. We hope to show that this solution decreases revisits to the emergency department and increases quality of life for patients.

Registry
clinicaltrials.gov
Start Date
October 31, 2016
End Date
November 2017
Last Updated
6 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Kendall Ho

Lead, Digital Emergency Medicine; Professor, Department of Emergency Medicine, Faculty of Medicine, UBC

University of British Columbia

Eligibility Criteria

Inclusion Criteria

  • PATIENT PARTICIPANTS:
  • Have one or more typical symptoms of Heart Failure (i.e. dyspnoea at rest or minimal exertion (includes orthopnoea, reduced exercise tolerance)) AND
  • Have one or more typical signs of Heart Failure (i.e. elevated jugular venous pressure, pulmonary crepitations, pleural effusions, peripheral oedema) AND
  • Have one or more objective measures of heart failure:
  • Radiological congestion.
  • Elevated BNP ≥ 400 pg/mL or NT-proBNP ≥ 1000 pg/mL.
  • Reduced left ventricular ejection fraction \<40% (or \<45%) in previous 12 months.
  • Diastolic dysfunction including tissue Doppler E/e' ratio \> 15 in previous 12 months.
  • Pulmonary capillary wedge pressure \>20 mmHg.
  • Diuretic therapy. The additional value of diuretic therapy (IV or oral) is debatable, as presumably unlikely (or unsafe) that patient with genuine HF will be discharged without diuretic.

Exclusion Criteria

  • PATIENT PARTICIPANTS:
  • Physical barriers e.g. unable to stand on scales.
  • Cognitive impairment (e.g. MMSE \<20), unless suitable caregiver support.
  • Language (must be able to read and understand English), unless suitable caregiver support.
  • Documented history of current and active substance misuse (within 3 months).
  • Lack digital connectivity or landline phone connection.
  • No regular care provider e.g. GP, or at least regular walk-in clinic.
  • Existing intensive system of care: LVAD, transplant, dialysis.
  • Anticipated improvement due to revascularization (PCI/CABG) or valve intervention during index hospitalization.
  • Anticipated survival \<90 days. Active palliative care, less-than level III care, disseminated malignancy.

Outcomes

Primary Outcomes

Change in number of emergency department revisits 90 day pre and 90 days post enrollment.

Time Frame: 90 days

Hospital administrative data and self-reported data will be reviewed to assess the number of emergency department visits 90 day pre and 90 days post enrollment.

Change in the length of stay (in days)

Time Frame: 90 days

Hospital administrative data and self-report data will be reviewed to assess the length of stay (measured in days) 90 day pre and 90 days post enrollment.

Change in the number of hospitalizations

Time Frame: 90 days

Hospital administrative data and self-report data will be reviewed to assess the number of hospitalizations 90 day pre and 90 days post enrollment.

Mortality rate

Time Frame: 90 days

The number of patients who pass away during the 90 day follow-up period will be recorded.

Secondary Outcomes

  • Difference in self-care efficacy scale scores as assessed by the European Heart Failure Self-care Behaviour Scale(90 Days)
  • Difference in quality of life (general) scores as assessed by the VR-12(90 Days)
  • Difference in quality of life (HF-specific) scores as assessed by the Kansas City Cardiomyopathy Questionnaire 12 (KCCQ-12) scale(90 days)
  • Impact of patient experience of care via interviews(90 days)
  • Difference in costs and savings via administrative data and a self-report healthcare utilization survey.(90 days)
  • Impact of patient experience of care via surveys(90 days)
  • Impact on communication between healthcare providers and patients via surveys(90 days)
  • Impact on communication between healthcare providers and patients via interviews(90 days)

Similar Trials